Bin Ma
Chief Scientist
Rapid Novor
9/10Traction
The startup develops protein sequencing technology that enables pharmaceutical companies to generate antibody proteins directly from samples with high sequence accuracy and binding affinity. Their method utilizes mass spectrometry to restore hybridoma cell lines, confirm antibody products, and analyze post-translational modifications, facilitating the efficient development of biosimilars for improved human health.
- Biotechnology
Updated 21 months ago
Funding
Raised to date
$5MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops protein sequencing technology that enables pharmaceutical companies to generate antibody proteins directly from samples with high sequence accuracy and binding affinity. Their method utilizes mass spectrometry to restore hybridoma cell lines, confirm antibody products, and analyze post-translational modifications, facilitating the efficient development of biosimilars for improved human health.